GC Biopharma Corp. (formerly Green Cross Corporation)
↗Yongin, Gyeonggi Province, South Korea
GC Biopharma is South Korea's leading biopharmaceutical company and one of the world's top plasma protein manufacturers with over 50 years of dedicated innovation in blood products and vaccines. The company specializes in plasma-derived therapeutics, recombinant protein treatments, vaccines, cell therapy manufacturing, and diagnostic services. GC Biopharma operates 45 affiliated companies globally (28 in Korea, 17 overseas) with a strong commitment to R&D, investing 5-7% of annual revenue in new drug development. The company is positioned as a global innovator focusing on rare diseases, immunological disorders, and next-generation therapeutics including mRNA platforms and cell therapy.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Biopharmaceutical
Sub-Industry:Plasma protein therapeutics, Vaccines, Rare disease, Cell therapy CDMO
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$1.7B (TTM as of 2025)
Founded:1967
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:Korea Exchange (KRX)
Ticker:006280.KS
PIPELINE
Stage:Multiple stages (Discovery through Commercial)
Lead Drug Stage:Hunterase (Hunter syndrome treatment) - Marketed; Alyglo (Immunodeficiency) - Marketed; GC1130A (Sanfilippo type A) - Phase 1 (FDA Fast Track); GC4006A (COVID-19 mRNA vaccine) - Phase 1
Modalities:Plasma-derived proteins, Recombinant proteins, Monoclonal antibodies, mRNA vaccines, Cell therapy, Vaccines (inactivated, recombinant), Medical devices
Trial Phases:Phase 1: 2 | Phase 3: 1
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:GC Pharma, GC Biopharma USA, Made Scientific (cell therapy CDMO, acquired 2022), GC Cell Corporation, GC LabTech (diagnostics), Curevo (vaccines), GC Wellbeing
Key Partnerships:Hanmi Pharmaceutical (Fabry disease treatment HM15421/GC1134A joint development), Immetas Therapeutics (mRNA therapeutics for autoimmune diseases), Novelty Nobility (antibody therapeutics for geographic atrophy), Curevo Vaccine (recombinant shingles vaccine CRV-101 contract manufacturing), Korea Disease Control and Prevention Agency (KDCA) - anthrax vaccine, Infectious Disease Research Institute (IDRI) - vaccine research, Syenex (T-cell therapy manufacturing partnership via Made Scientific)
COMPETITION
Position:Leader (Korea); Challenger (Global plasma proteins); Emerging (Cell therapy CDMO, mRNA vaccines)
Competitors:Roche, Novartis, Hanmi Pharmaceutical, Daewoong Pharmaceutical, Yuhan Corporation, Dong-A ST, CSL Behring, Grifols
LEADERSHIP
Key Executives:
Il-sup Huh - Chairman & CEO (parent company level)
Dr. Eun-chul Huh - President & CEO (GC Biopharma operations)
Woo Jin Lee - Senior Vice President; CEO of GC Biopharma USA
Dr. Lisa M. Betts - Executive Leadership, GC Biopharma USA
Park Chung-kwon - CEO of GC Green Cross EM (E4 level)
Kim Yeon-geun - CEO of GC Green Cross MS (E3 level)
Scientific Founders:Young-sup Huh (founder/first CEO and chairman, 1970)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of GC Biopharma Corp. (formerly Green Cross Corporation) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with GC Biopharma Corp. (formerly Green Cross Corporation). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.